Walleye Capital LLC Biocryst Pharmaceuticals Inc Call Options Transaction History

Walleye Capital LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$6.41 - $8.69 $8,974 - $12,166	1,400 New	1,400 $10,000
Q1 2024 May 15, 2024	SELL	$4.89 - $7.65 $152,079 - $237,915	-31,100 Reduced 55.64%	24,800 $125,000
Q4 2023 Feb 14, 2024	SELL	$4.98 - $6.77 $70,716 - $96,134	-14,200 Reduced 20.26%	55,900 $334,000
Q3 2023 Nov 14, 2023	BUY	$6.71 - $7.92 $365,695 - $431,640	54,500 Added 349.36%	70,100 $496,000
Q2 2023 Aug 14, 2023	BUY	$6.96 - $8.81 $20,880 - $26,430	3,000 Added 23.81%	15,600 $109,000
Q1 2023 May 15, 2023	SELL	$7.94 - $11.84 $192,148 - $286,528	-24,200 Reduced 65.76%	12,600 $105,000
Q4 2022 Feb 14, 2023	SELL	$10.5 - $14.2 $176,400 - $238,560	-16,800 Reduced 31.34%	36,800 $422,000
Q3 2022 Nov 14, 2022	BUY	$10.79 - $14.81 $578,344 - $793,816	53,600 New	53,600 $675,000

279

172M

625K

739K

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.41B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Walleye Capital LLC with notifications on news.